Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for a substantial proportion of liver diseases worldwide. The two viruses share same modes of transmission, coinfection is not uncommon, especially among high risk populations.

Hepatitis C Testing in the Community

This booklet provides a comprehensive overview of HCV testing in the community, looking at benefits, effective models, public health burden, policy and barriers.

English PDF Document

Online Peer Support Manual

This website provides access to comprehensive resources for organisations and peer workers. Here you can find information on how to support peer workers from organisations and the peer workers.

English PDF Document

Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection

Molecular testing atthe point-of-care may turn outto be game changer for HCVdiagnosis and treatment monitoring, through increased sensitivity, reduced turnaround time, and ease of performance. One such assay GeneXpert® has recently been released. Comparative analysis between performances of GeneXpert® and Abbott HCV-RNA was done

English PDF Document

Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Martinello et al

One challenge to achieving HCV elimination through therapeutic intervention is reinfection. There is concern that HCV reinfection may compromise HCV treatment outcomes in populations with ongoing risk behaviors, with the risk of reinfection cited as a reason for not offering treatment to PWID. This review summarizes the literature regarding reinfection after successful HCV treatment among PWID, discusses strategies to reduce HCV infection and reinfection, and highlights the potential individual- and population-level impact of DAA treatmentscale up on HCV elimination.

English Website

Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs. Heimer et al.

Hepatitis C virus could not be recovered from cookers regardless of input syringe type or cooker design. Recovery was higher when comparing detachable needles to fxed needles for residue in input syringes (73.8% vs 0%), flters (15.4% vs 1.4%), and receptive syringes (93.8% vs 45.7%).

English Website

M. Hellard et al. Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond

The implication of this work is that for many countries the elimination of hepatitis C as a public health threat is not going to happen by chance. A number of barriers need to be overcome, requiring a focused effort from governments and health services. The first barrier is that widespread treatment scale-up is currently precluded by restricted and inconsistent access policies in many European countries.3,4

English Website

Micro-elimination – A path to global elimination of hepatitis C

The micro-elimination approach encourages policymakers and other stakeholders to set pragmatic national and subnational goals, while the people who are best informed about the nature of the HCV epidemic in their sub-population can take the lead in tailoring interventions to address its specific circumstances.

English Website

Legal Barriers for Providing HCV Community Testing in Europe

Correlation European Harm Reduction Network conducted a telephone survey with representatives of harm reduction services and of NGOs that offer low-threshold services to drug users. During the months of September and October 2018, a total of twenty (20) organizations in 18 countries, participated in this survey and provided information on the state of affairs with regards to community testing in their country

English PDF Document

In partnership with:
Correlation Network